Zhejiang Jingxin Pharmaceutical Co., Ltd. cancelled the acquisition of 15% stake in Shanghai Ruitai Biological Technology Co., Ltd.
January 27, 2017
Share
Zhejiang Jingxin Pharmaceutical Co., Ltd. (SZSE:002020) agreed to acquire 15% stake in Shanghai Ruitai Biological Technology Co., Ltd for approximately CNY 58.4 million on January 28, 2016. Zhejiang Jingxin Pharmaceutical Co., Ltd. will sign the agreement. The transaction price and the number of stake to be transferred will be based on the formal investment agreement signed between Zhejiang Jingxin Pharmaceutical and Shanghai Ruitai Biological Technology. The Board of Zhejiang Jingxin Pharmaceutical approved the transaction on January 28, 2016.
Zhejiang Jingxin Pharmaceutical Co., Ltd. (SZSE:002020) cancelled the acquisition of 15% stake in Shanghai Ruitai Biological Technology Co., Ltd as of January 28, 2017.
ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. is a China-based company engaged in manufacture of pharmaceuticals. The Company's pharmaceutical products include chemical pharmaceuticals, traditional medicines, biological agents and bulk pharmaceutical chemicals. Its pharmaceutical products are mainly applied in cardiovascular sector, digestive tract sector and psychoneural sector, among others. The Company is also engaged in the research and development, manufacture and sales of medical devices. Its medical devices include clinical displays, diagnosis displays, endoscopic surgery displays and ultrasonic image displays, among others. The Company operates its businesses in both domestic and overseas markets.
ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. 
